Drug intelligence / Profile preview

Heliogen

Development stage: Unknown
Lead developer: MIMEDX
Modality: Adoptive Cell Transfer → Cell Therapies, Other Cell Types → Cell Therapies, Stem Cell Therapies → Cell Therapies
Administration: Topical

Overview

Heliogen is a placental-derived surgical biologic developed by MiMedx for use in tissue repair and surgical applications. As an amnion-derived allograft, it is processed to retain the natural biological components of human placental tissue, including a scaffold of extracellular matrix (ECM) proteins, growth factors, and cytokines. These elements work together to provide a biocompatible environment that supports the body's endogenous healing response and provides structural reinforcement at the surgical site. Heliogen is marketed as an advanced surgical solution for various procedures requiring tissue regeneration and wound closure.

Brand names: Heliogen

Beyond the preview

Go deeper on Heliogen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heliogen.

Explore the full profile